• Home
  • Murli Krishna Pharma Pvt. Ltd.

Murli Krishna Pharma Pvt. Ltd.

  • Company Brochure
  • Product Portfolio
About Murli Krishna Pharma Pvt. Ltd.

Established in 2004, Murli Krishna Pharma has emerged as a pioneer in providing cutting-edge drug delivery solutions. With accreditations of EUMGP and WHO-GMP, we utilize proprietary technologies such as modified, dual delayed, sustained release, and taste masking. Our extensive product portfolio encompasses a wide array of pre-formulations (PFI) of oral solid dosage formulations including pellets, granules, and MUPS. it boasts modern machinery and facilities compliant with 21 CFR, part 11 standards.

Read more Show less
Certifications
  • GMP
    GMP
  • Other
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • IN
  • 2016
    On CPHI since
  • 2
    Certificates
  • 250 - 499
    Employees
Company types
Manufacturer/Innovator
Primary activities
Custom Manufacturing/Custom Synthesis
View company profile
Contact info
  • +91 2138675600
  • Website
  • D-98, MIDC Ranjangaon, Taluka - Shirur, 412209, Pune (Dist.), Maharasthra, India
Show contact info Hide contact info
Meet us at

CPHI Americas 2025

Pennsylvania Convention Center, Philadelphia
20 May 2025 - 22 May 2025
View Exhibitor Profile

CPHI Frankfurt 2025

Messe, Frankfurt
28 Oct 2025 - 30 Oct 2025
View Exhibitor Profile

Products from Murli Krishna Pharma Pvt. Ltd. (28)

  • CLARITHROMYCIN MICRO PELLETS 27.5%W/W :(CLARITHROMYCIN Enteric Coated pellets 27.5%w/w)

    Product CLARITHROMYCIN MICRO PELLETS 27.5%W/W :(CLARITHROMYCIN Enteric Coated pellets 27.5%w/w)

    Physical Specifications: White to off white spherical pellets, Pellets Size: ASTM 30#80. Release specification: As per latest USP std, including additional parameters i.e. Related Substances (RS/impurities) and Microbiological (Ready To Fill size 0 Capsule, for Hard Gelatin Capsule ...
  • ITRACONAZOLE PELLETS 22% W/W:

    Product ITRACONAZOLE PELLETS 22% W/W:

    ITRACONAZOLE PELLETS 22% W/W:

    Specifications: White to off white spherical pellets,
    Pellets Size:  ASTM16#20: 
    Release specification: As per latest USP std.
    Fill Weight: 
    For 100mg capsule: 455mg pellets filled in SIZE 0 capsules. 1 kg of Pellets can ...
  • LANSOPRAZOLE Micro PELLETS 12.5%W/W: (Lansoprazole Enteric Coated Micro pellets 12.5%)

    Product LANSOPRAZOLE Micro PELLETS 12.5%W/W: (Lansoprazole Enteric Coated Micro pellets 12.5%)

    LANSOPRAZOLE Micro PELLETS 12.5%W/W: (Lansoprazole Enteric Coated Micro pellets 12.5%)

    Physical Specifications: White to off while spherical pellets, Pellets Size: ASTM 30#50, ASTM 25#50

    Release specification: As per latest USP std. including additional parameters i.e. ...
  • Lansoprazole Pellets 8.5%

    Product Lansoprazole Pellets 8.5%

    We Murli Krishna Pharma specialised in the manufacture of Pharmaceutical Pellets/ Micro Pellets / Granules and MUPS.We manufacture Lansoprazole Pellets 8.5%( Product complies to USP) Particle size:  ( 14 #18), ( 16 #20) and ( 30 #80) Comparative Dissolution:  The profile matches...
  • Omeprazole PELLETS 8.5%W/W: (OmeprazoleEnteric Coated pellets 8.5%w/w)

    Product Omeprazole PELLETS 8.5%W/W: (OmeprazoleEnteric Coated pellets 8.5%w/w)

    Omeprazole PELLETS 8.5%W/W: (OmeprazoleEnteric Coated pellets 8.5%w/w)


    Physical Specifications: 

    White to off while spherical pellets, Pellets Size: ASTM 14#18.

    Release specification: As per latest USP std. including additional parameters i.e. Related...
  • Azithromycin Taste Masked Pellets

    Product Azithromycin Taste Masked Pellets

    The objective of developing Azithromycin taste masked micro pellets (Multiple unit particulate system i.e. MUPS) by aqueous technology is to fill the micro pellets in to capsule, are compressed into tablet and also are constituted to make the oral suspension.
  • Brinzolamide

    Product Brinzolamide

    MKPPL developed a Nano particle based matrix which can deliver hydrophilic as well as hydrophobic drugs using a combination of hydrophilic and hydrophobic excipients as a clear solution. This cogent use of excipients ensures that the drug is absorbed optimally and the Nano particles ensure that the dru...
  • Budesonide

    Product Budesonide

    There is a potential for the development of inhalation medicines in lipid Nano particles to possess controlled release properties. MKPPL’s Budesonide suspension has been developed in a complete aqueous base using a couple of specialized solubilizers which also helps in the Nano encapsulation of the drug.
  • Dexlansoprazole Pellets

    Product Dexlansoprazole Pellets

    The pharmaceutical form of dexlansoprazole is based on the unique technology of modified dual release. The active ingredient is released in two phases at different pH values and with a time interval. Consequently, the drug achieves two peak concentrations in the blood, and the total serum concentration...
  • Duloxetine

    Product Duloxetine

    The objective is to develop Duloxetine DR pellets by aqueous technology. Pellets developed by aqueous technology have advantage of avoiding the use of organic solvents
  • Erlotinib MUPS, Granules

    Product Erlotinib MUPS, Granules

    Murli Krishna Pharma developed a Nano particle based premix for direct compression into tablets. The premix was developed using the following approach: 1)            Enhance the solubility of Erlotinib at near neutral pH. 2)  ...
  • Esomeprazole MUPS 22.5%

    Product Esomeprazole MUPS 22.5%

    MUPS have distinct advantages over single unit system such as multiple unit particles get distributed throughout the GI tract thereby avoiding localized accumulation. MUPS developed by aqueous technology have also advantage of avoiding the use of organic solvents.
show all 28 products

Murli Krishna Pharma Pvt. Ltd. Resources (6)

  • Company Profile and Product Portfolio

    Brochure Company Profile and Product Portfolio

  • Corporate Brochure

    Brochure Corporate Brochure

    Murli Krishna Pharma Pvt Ltd is a young and dynamic Novel Drug Delivery Systems (NDDS) organization that provides a range of effective solutions to optimize the delivery of pharmaceutical products. Our current activities include manufacturing of pre-finished formulations i.e. Pellets, Granules and MUPS using Aqueous Based technology, Nano Particles and Transdermal Oil.

  • Tamsulosin HCL SR Pellets 0.125%, 0.13%, 0.16%, 0.20%

    Brochure Tamsulosin HCL SR Pellets 0.125%, 0.13%, 0.16%, 0.20%

    Tamsulosin HCL SR pellets is developed using an Aqueous platform and our USP lies in complying with all the US Pharmacoepial specifications. With a formulation that is in line with the Innovator product in terms of release profile, We extensively use Extrusion spheronization process besides the wurster process
  • Nab Paclitaxel (Albumin Bound)

    Video Nab Paclitaxel (Albumin Bound)

    Murli Krishna Pharma is one of the few companies from India who have developed Albumin bound Paclitaxel. The particle size and the encapsulation efficiency have matched with the innovator’s specifications. In Vitro Cell line studies have shown that the activity is comparable to the innovator.
    2020-09-08
  • Orlistat Pellets 50%

    Video Orlistat Pellets 50%

    Leading Manufacturer from India for Orlistat pellets. Offering a product matching the Innovator's release profile, our product does not infringe with the patent.
    2020-09-08
  • Iron & Vitamin Liposomal Transdermal

    Video Iron & Vitamin Liposomal Transdermal

    A Topical administration route had been chosen for the first time for Iron and Vitamins. With Minimal to Zero side effects, the absorption is almost close to 60% when compared to that of the oral route where the absorption is less than 20%. With a strong back up of clinicals on infants, this product of Murli Krishna Pharma is in the process of getting patented
    2020-09-08